Erastin: Ferroptosis Inducer for Cancer Biology and Oxidative Stress Research

Executive Summary: Erastin (CAS 571203-78-6), available as SKU B1524 from APExBIO, is a chemically defined small molecule that induces ferroptosis, a caspase-independent, iron-dependent form of regulated cell death, particularly in tumor cells harboring oncogenic RAS or BRAF mutations (APExBIO). Its action is mediated by inhibition of the cystine/glutamate antiporter system Xc⁻ and modulation of the voltage-dependent anion channel (VDAC), leading to lethal lipid ROS accumulation (Liu et al., 2021). Erastin is widely used in preclinical research to dissect oxidative stress responses and to explore ferroptosis as a therapeutic vulnerability in oncology. Experimental protocols commonly use 10 μM Erastin for 24 hours in engineered human tumor cells or HT-1080 fibrosarcoma cells, with solutions freshly prepared in DMSO. Key limitations include poor aqueous solubility and instability in solution, requiring careful handling and storage at -20°C. These properties make Erastin a reference compound for benchmarking ferroptosis and oxidative stress assays (Gentamycin-Sulfate, 2023).

Biological Rationale

Ferroptosis is a genetically and biochemically distinct, iron-dependent cell death pathway characterized by the accumulation of lipid peroxides. Unlike apoptosis or necroptosis, ferroptosis does not require caspase activation or RIPK3/MLKL signaling (Liu et al., 2021). Tumor cells with mutations in RAS (HRAS, KRAS) or BRAF exhibit heightened sensitivity to oxidative stress and ferroptotic triggers. The cystine/glutamate antiporter system Xc⁻ is essential for cellular redox homeostasis by importing cystine for glutathione synthesis. Inhibition of this transporter depletes intracellular glutathione, reducing the cell's capacity to neutralize reactive oxygen species (ROS). Voltage-dependent anion channels (VDACs) on the mitochondrial outer membrane regulate metabolite and ion flux, contributing to mitochondrial function and redox balance. Targeting these pathways provides a means to selectively induce cell death in cancer cells with defined genetic backgrounds, while sparing normal tissues (Heparin-Cofactor-II, 2023). This article extends previous discussions by delivering structured evidence on Erastin's selectivity and robust use in oxidative stress models.

Mechanism of Action of Erastin

Erastin induces ferroptosis by two complementary mechanisms. First, it directly inhibits system Xc⁻, a cystine/glutamate antiporter composed of SLC7A11 and SLC3A2 subunits, reducing cystine uptake and intracellular glutathione (GSH) levels. Glutathione is a critical antioxidant required for the activity of glutathione peroxidase 4 (GPX4), which detoxifies lipid hydroperoxides. Depletion of GSH disables GPX4, permitting accumulation of toxic lipid ROS and membrane damage.

Second, Erastin binds and modulates the voltage-dependent anion channel (VDAC) on the mitochondrial outer membrane. VDAC modulation alters mitochondrial permeability and promotes oxidative stress, further amplifying ROS accumulation. This leads to a non-apoptotic, iron-dependent cell death cascade distinct from necroptosis or apoptosis (Liu et al., 2021).

Ferroptosis induced by Erastin is strictly iron-dependent: chelation of iron with deferoxamine blocks the effect, confirming the specificity of the pathway. Notably, Erastin-induced cell death is not associated with caspase activation or DNA fragmentation, distinguishing it from classical apoptosis. Unlike necroptosis, Erastin’s effects do not rely on RIPK3 or MLKL, as shown by resistance in cells lacking these adaptors (Liu et al., 2021).

Evidence & Benchmarks

• Erastin selectively induces ferroptosis in tumor cells with mutant RAS or BRAF, sparing normal cells (DOI: 10.1016/j.immuni.2020.11.020).
• System Xc⁻ inhibition by Erastin reduces cellular cystine import and GSH levels within 2–6 hours at 10 μM in HT-1080 cells (DOI: 10.1016/j.immuni.2020.11.020).
• Erastin's effects are blocked by iron chelators and lipid peroxidation inhibitors, confirming ferroptosis specificity (DOI: 10.1016/j.immuni.2020.11.020).
• The product is insoluble in water and ethanol, but dissolves in DMSO at ≥10.92 mg/mL with gentle warming (APExBIO product page).
• Freshly prepared Erastin solutions remain stable for short-term use; long-term stability is optimal only in solid form at -20°C (Capsazepine, 2023).

Applications, Limits & Misconceptions

Erastin is widely used to investigate ferroptosis, cancer therapy targeting ferroptosis, and oxidative stress in RAS/BRAF-mutant tumors. Standard applications involve treatment of engineered human tumor cells or HT-1080 fibrosarcoma cells at 10 μM for 24 hours in serum-containing media, with DMSO as solvent. Erastin is also valuable in high-throughput screening for ferroptosis modulators and in mechanistic dissection of redox pathways.

Previous articles, such as "Erastin: Ferroptosis Inducer Transforming Cancer Biology", focus on actionable protocols and troubleshooting, whereas this article emphasizes the molecular rationale, evidence base, and limitations for advanced practitioners.

Common Pitfalls or Misconceptions

• Not a pan-cancer agent: Erastin is effective primarily in RAS- or BRAF-mutant cells; many wild-type cancer lines are resistant.
• Not an apoptosis or necroptosis inducer: Erastin does not activate caspases or require RIPK3/MLKL, distinguishing it from other cell death triggers (Liu et al., 2021).
• Solubility constraints: Erastin is insoluble in water or ethanol; improper dissolution can lead to inconsistent dosing.
• Not suitable for long-term stock solutions: Erastin degrades in solution; always prepare fresh DMSO stocks before use (APExBIO).
• Iron-dependent: Effects can be masked in iron-deficient or chelator-containing media.

Workflow Integration & Parameters

For optimal use, Erastin (SKU B1524 from APExBIO) should be dissolved in DMSO at ≥10.92 mg/mL with gentle warming. Working concentrations of 10 μM in cell culture medium are typical for HT-1080 or engineered cancer cell lines, with treatment durations of 24 hours. Solutions should be freshly prepared to ensure stability and reproducibility. Store the solid compound at -20°C, protected from light and moisture. Do not store Erastin as a solution for more than a few hours, as degradation may impact results. For negative controls, use DMSO vehicle or iron chelators (e.g., deferoxamine) to confirm pathway specificity. For further workflow guidance, see "Erastin (SKU B1524): Reliable Ferroptosis Induction for A...", which provides complementary troubleshooting and assay optimization details.

Conclusion & Outlook

Erastin is a rigorously validated, mechanistically defined ferroptosis inducer with unique selectivity for RAS/BRAF-mutant tumor models. Its dual targeting of system Xc⁻ and VDAC distinguishes it from other cell death inducers and underpins its prominence in oxidative stress and cancer biology research. APExBIO's Erastin (SKU B1524) offers batch-tested reliability for quantitative and reproducible cell death assays (product page). Future research will clarify Erastin's translational potential in precision oncology and its integration with immunotherapies. For detailed protocol scenarios and advanced applications, the article "Erastin (SKU B1524): Scenario-Driven Solutions for Ferroptosis" addresses laboratory-specific challenges beyond the mechanistic focus of this dossier.